Suchergebnisse - "Pro, Barbara"

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial von Kim, Youn H, Bagot, Martine, Pinter-Brown, Lauren, Rook, Alain H, Porcu, Pierluigi, Horwitz, Steven M, Whittaker, Sean, Tokura, Yoshiki, Vermeer, Maarten, Zinzani, Pier Luigi, Sokol, Lubomir, Morris, Stephen, Kim, Ellen J, Ortiz-Romero, Pablo L, Eradat, Herbert, Scarisbrick, Julia, Tsianakas, Athanasios, Elmets, Craig, Dalle, Stephane, Fisher, David C, Halwani, Ahmad, Poligone, Brian, Greer, John, Fierro, Maria Teresa, Khot, Amit, Moskowitz, Alison J, Musiek, Amy, Shustov, Andrei, Pro, Barbara, Geskin, Larisa J, Dwyer, Karen, Moriya, Junji, Leoni, Mollie, Humphrey, Jeffrey S, Hudgens, Stacie, Grebennik, Dmitri O, Tobinai, Kensei, Duvic, Madeleine, Abhyankar, Sunil, Akilov, Oleg, Alpdogan, Onder, Beylot-Barry, Marie, Boh, Erin, Caballero, Dolores, Cowan, Richard, Dreno, Brigitte, Dummer, Reinhard, Fenske, Timothy, Foss, Francine, Fukuhara, Noriko, Giri, Pratyush, Habe, Koji, Hamada, Toshihisa, Hatake, Kiyohiko, Iida, Shinsuke, Ishikawa, Osamu, Iversen, Lars, Kiyohara, Eiji, Koga, Hiroshi, Korman, Neil, Kuss, Bryone Jean, Lamar, Zanetta, Lansigan, Frederick, Lechowicz, Mary Jo, Lerner, Adam, Magnolo, Nina, Mark, Lawrence, Miyagaki, Tomomitsu, Munoz, Javier, Nicolay, Jan Peter, Nishiwaki, Kaoru, Okamoto, Hiroyuki, Ohtsuka, Mikio, Pacheco, Theresa, Querfeld, Christiane, Rapini, Ronald Peter, Sano, Shigetoshi, Tanaka, Maiko, Tharp, Michael D., Uehara, Jiro, Wada, Hidefumi, Wells, Jillian, Wilcox, Ryan A., William, Basem, Yonekura, Kentaro

“… Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of …”
Volltext

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study von Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L, Rosenblatt, Joseph D, Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M, Yang, Yin, Sievers, Eric L, Kennedy, Dana A, Shustov, Andrei

“… Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug …”
Weitere Angaben

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy von Coiffier, Bertrand, Pro, Barbara, Prince, H Miles, Foss, Francine, Sokol, Lubomir, Greenwood, Matthew, Caballero, Dolores, Borchmann, Peter, Morschhauser, Franck, Wilhelm, Martin, Pinter-Brown, Lauren, Padmanabhan, Swaminathan, Shustov, Andrei, Nichols, Jean, Carroll, Susan, Balser, John, Balser, Barbara, Horwitz, Steven

“… Romidepsin is a structurally unique, potent class 1 selective histone deacetylase inhibitor. The primary objective of this international, pivotal, single-arm, …”
Weitere Angaben

Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E) von Park, Joonhee, Yang, Jingyi, Wenzel, Alexander T, Ramachandran, Akshaya, Lee, Wung J, Daniels, Jay C, Kim, Juhyun, Martinez-Escala, Estela, Amankulor, Nduka, Pro, Barbara, Guitart, Joan, Mendillo, Marc L, Savas, Jeffrey N, Boggon, Titus J, Choi, Jaehyuk

“… Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early-stage disease, lesions are limited to the skin, but …”
Weitere Angaben

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study von O'Connor, Owen A, Pro, Barbara, Pinter-Brown, Lauren, Bartlett, Nancy, Popplewell, Leslie, Coiffier, Bertrand, Lechowicz, Mary Jo, Savage, Kerry J, Shustov, Andrei R, Gisselbrecht, Christian, Jacobsen, Eric, Zinzani, Pier Luigi, Furman, Richard, Goy, Andre, Haioun, Corinne, Crump, Michael, Zain, Jasmine M, Hsi, Eric, Boyd, Adam, Horwitz, Steven

“… Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy …”
Weitere Angaben

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project von Federico, Massimo, Bellei, Monica, Marcheselli, Luigi, Luminari, Stefano, Lopez-Guillermo, Armando, Vitolo, Umberto, Pro, Barbara, Pileri, Stefano, Pulsoni, Alessandro, Soubeyran, Pierre, Cortelazzo, Sergio, Martinelli, Giovanni, Martelli, Maurizio, Rigacci, Luigi, Arcaini, Luca, Di Raimondo, Francesco, Merli, Francesco, Sabattini, Elena, McLaughlin, Peter, Solal-Céligny, Philippe

“… The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate prognostic index for follicular …”
Weitere Angaben

Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas von Daniels, Jay, Doukas, Peter G., Escala, Maria E. Martinez, Ringbloom, Kimberly G., Shih, David J. H., Yang, Jingyi, Tegtmeyer, Kyle, Park, Joonhee, Thomas, Jane J., Selli, Mehmet E., Altunbulakli, Can, Gowthaman, Ragul, Mo, Samuel H., Jothishankar, Balaji, Pease, David R., Pro, Barbara, Abdulla, Farah R., Shea, Christopher, Sahni, Nidhi, Gru, Alejandro A., Pierce, Brian G., Louissaint, Abner, Guitart, Joan, Choi, Jaehyuk

“… Primary cutaneous γδ T cell lymphomas (PCGDTLs) represent a heterogeneous group of uncommon but aggressive cancers. Herein, we perform genome-wide DNA, RNA, …”
Volltext

P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY von Mehta-Shah, Neha, Jacobsen, Eric, Luigi Zinzani, Pier, Zain, Jasmine, Mead, Monica, Casulo, Carla, Gritti, Giuseppi, Pinter-Brown, Lauren, Izutsu, Koji, Waters, Sheila, Brammer, Jonathan, Pro, Barbara, Horwitz, Steven

Volltext

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium von Smith, Sonali M, van Besien, Koen, Karrison, Theodore, Dancey, Janet, McLaughlin, Peter, Younes, Anas, Smith, Scott, Stiff, Patrick, Lester, Eric, Modi, Sanjiv, Doyle, L Austin, Vokes, Everett E, Pro, Barbara

“… Despite high initial remission rates, most lymphomas relapse and require further therapy. The mammalian target of rapamycin (mTOR) pathway is a validated …”
Weitere Angaben

Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database von Solal-Céligny, Philippe, Bellei, Monica, Marcheselli, Luigi, Pesce, Emanuela Anna, Pileri, Stefano, McLaughlin, Peter, Luminari, Stefano, Pro, Barbara, Montoto, Silvia, Ferreri, Andrés J M, Deconinck, Eric, Milpied, Noël, Gordon, Leo I, Federico, Massimo

“… Patients with follicular lymphoma (FL) registered in the F2-study and initially managed without treatment were analyzed to describe the presentation and …”
Weitere Angaben

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma von Tam, Constantine S, Bassett, Roland, Ledesma, Celina, Korbling, Martin, Alousi, Amin, Hosing, Chitra, Kebraei, Partow, Harrell, Robyn, Rondon, Gabriela, Giralt, Sergio A, Anderlini, Paolo, Popat, Uday, Pro, Barbara, Samuels, Barry, Hagemeister, Frederick, Medeiros, L Jeffrey, Champlin, Richard E, Khouri, Issa F

“… In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential …”
Weitere Angaben

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial von Foss, Francine, Horwitz, Steven, Pro, Barbara, Prince, H. Miles, Sokol, Lubomir, Balser, Barbara, Wolfson, Julie, Coiffier, Bertrand

“… Background Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and …”
Volltext

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma von Iyer, Swaminathan, Trümper, Lorenz, O’Connor, Owen A., Pro, Barbara, Illidge, Tim, Advani, Ranjana, Bartlett, Nancy L., Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Menne, Tobias, Belada, David, Illès, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei, Hüttmann, Andreas, Savage, Kerry J., Yuen, Sam, Zinzani, Pier Luigi, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, Horwitz, Steven

Volltext

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease von Adam M. Petrich, Barbara Pro, Valerie Nelson, Jane N. Winter, Deborah M. Stephens, Shuo Ma, Leo I. Gordon, Ephraim P. Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Juehua Gao, Reem Karmali, Frank Kuhr, Jason B. Kaplan, Ronald W. Takvorian

Volltext

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma von Goy, Andre, Younes, Anas, McLaughlin, Peter, Pro, Barbara, Romaguera, Jorge E, Hagemeister, Frederick, Fayad, Luis, Dang, Nam H, Samaniego, Felipe, Wang, Michael, Broglio, Kristine, Samuels, Barry, Gilles, Frederic, Sarris, Andreas H, Hart, Susan, Trehu, Elizabeth, Schenkein, David, Cabanillas, Fernando, Rodriguez, Alma M

“… Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Patients were stratified, based on …”
Weitere Angaben

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy von Karmali, Reem, Shouse, Geoffrey, Torka, Pallawi, Moyo, Tamara K., Romancik, Jason, Barta, Stefan K., Bhansali, Rahul, Cohen, Jonathon B., Shah, Nirav N., Zurko, Joanna, Kenkre, Vaishalee P., Hess, Brian, Stephens, Deborah M., Fitzgerald, Lindsey, Ollila, Thomas, Tabiti, Bukky, Roy, Ishan, Ma, Shuo, Winter, Jane, Pro, Barbara, Moreira, Jonathan, Danilov, Alexey V., David, Kevin, Gordon, Leo I., Epperla, Narendranath

“… Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this …”
Volltext

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine von Romaguera, Jorge E, Fayad, Luis, Rodriguez, Maria A, Broglio, Kristine R, Hagemeister, Frederick B, Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Sarris, Andreas H, Dang, Nam H, Wang, Michael, Beasley, Virginia, Medeiros, L Jeffrey, Katz, Ruth L, Gagneja, Harish, Samuels, Barry I, Smith, Terry L, Cabanillas, Fernando F

“… To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients …”
Weitere Angaben

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2 von Savage, Kerry J., Horwitz, Steven M., Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O’Connor, Owen A., Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, Iyer, Swaminathan

“… •Consolidative SCT should be considered in patients with CD30+PTCL in a CR following frontline treatment with A+CHP.•Further studies are needed to establish …”
Volltext

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up von Domingo-Domènech, Eva, Pro, Barbara, Illidge, Tim, Horwitz, Steven, Trumper, Lorenz, Iyer, Swami, Advani, Ranjana, Bartlett, Nancy L., Christensen, Jacob Haaber, Kim, Won-Seog, Feldman, Tatyana, Choi, Ilseung, Gritti, Giuseppe, Belada, David, Shustov, Andrei, Illes, Arpad, Zinzani, Pier Luigi, Hüttmann, Andreas, Trneny, Marek, Le Gouill, Steven, Jagadeesh, Deepa, Friedberg, Jonathan W., Little, Meredith, Dong, Cassie, Fanale, Michelle, Fenton, Keenan, Savage, Kerry J.

“… Trial registration: ClinicalTrials.gov number: NCT01777152 …”
Volltext

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant von Savage, Kerry J., Horwitz, Steven M., Advani, Ranjana H., Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei R., Trneny, Marek, Yuen, Sam, Zinzani, Pier-Luigi, Truemper, Lorenz, Illidge, Timothy, O'Connor, Owen A, Pro, Barbara, Little, Meredith, Bunn, Veronica, Fenton, Keenan, Manley, Thomas, Iyer, Swaminathan P.

Volltext